Popa Irene Paula, Clim Andreea, Pînzariu Alin Constantin, Lazăr Cristina Iuliana, Popa Ștefan, Tudorancea Ivona Maria, Moscalu Mihaela, Șerban Dragomir N, Șerban Ionela Lăcrămioara, Costache-Enache Irina-Iuliana, Tudorancea Ionuț
Department of Morpho-Functional Sciences II, Discipline of Physiology, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iași, Romania.
2nd Department of Surgery-Pediatric Surgery and Orthopedics, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iași, Romania.
J Clin Med. 2024 Oct 4;13(19):5927. doi: 10.3390/jcm13195927.
Arterial hypertension (HTN) is one of the major global contributors to cardiovascular diseases and premature mortality, particularly due to its impact on vital organs and the coexistence of various comorbidities such as chronic renal disease, diabetes, cerebrovascular diseases, and obesity. Regardless of the accessibility of several well-established pharmacological treatments, the percentage of patients achieving adequate blood pressure (BP) control is still significantly lower than recommended levels. Therefore, the pharmacological and non-pharmacological management of HTN is currently the major focus of healthcare systems. Various strategies are being applied, such as the development of new pharmacological agents that target different underlying physiopathological mechanisms or associated comorbidities. Additionally, a novel group of interventional techniques has emerged in recent years, specifically for situations when blood pressure is not properly controlled despite the use of multiple antihypertensives in maximum doses or when patients are unable to tolerate or desire not to receive antihypertensive medications. Nonetheless, reducing the focus on antihypertensive medication development by the pharmaceutical industry and increasing recognition of ineffective HTN control due to poor drug adherence demands ongoing research into alternative approaches to treatment. The aim of this review is to summarize the potential novel pharmacological targets for the treatment of arterial hypertension as well as the future perspectives of the treatment strategy.
动脉高血压（HTN）是全球心血管疾病和过早死亡的主要促成因素之一，特别是因为它对重要器官有影响，并且存在各种合并症，如慢性肾病、糖尿病、脑血管疾病和肥胖症。尽管有几种成熟的药物治疗方法可供使用，但血压得到充分控制的患者比例仍显著低于推荐水平。因此，HTN的药物和非药物管理目前是医疗系统的主要关注点。正在应用各种策略，例如开发针对不同潜在生理病理机制或相关合并症的新型药物。此外，近年来出现了一组新型介入技术，特别是针对尽管使用了最大剂量的多种抗高血压药物但血压仍未得到适当控制的情况，或者患者无法耐受或不愿接受抗高血压药物的情况。尽管如此，制药行业减少对抗高血压药物研发的关注，以及由于药物依从性差导致对无效的HTN控制的认识增加，都需要对替代治疗方法进行持续研究。本综述的目的是总结治疗动脉高血压的潜在新型药理学靶点以及治疗策略的未来前景。
